Brian Gross, MD
Critical Care Medicine · Davenport, IANPI 1740255348
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $386 and has fallen 58.0% since, to $162 in 2025.
Across 62 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$135
- Insmed, Inc.$117
- Abiomed$100
- Pfizer$78
- Takeda Pharmaceuticals U.S.A., Inc.$68
- Boehringer Ingelheim$67
- plus $548 from 21 others
What the payments were for
- Food & beverage$1,08197%
- Education$313%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $135 |
| Insmed, Inc. | 6 | $117 |
| Abiomed | 3 | $100 |
| Pfizer | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| Boehringer Ingelheim | 4 | $67 |
| Regeneron Healthcare Solutions, Inc. | 3 | $60 |
| United Therapeutics Corporation | 2 | $45 |
| Ambu Inc. | 2 | $44 |
| Grifols USA, LLC | 2 | $35 |
| Sanofi | 2 | $34 |
| GSK | 2 | $34 |
| Electromed, Inc. | 3 | $32 |
| Mylan Specialty L.p. | 2 | $30 |
| Shire North American Group Inc | 2 | $29 |
| Verona Pharma, Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $22 |
| AbbVie | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Bayer | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Olympus America Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Veran Medical Technologies, Inc. | 1 | $10 |
How this compares
$1,112 in reported general payments places this provider in the 65th percentile of 33 critical care medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 22 | $323,080 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 375 | $305,686 |
| Spiriva RespimatTiotropium Bromide | 206 | $130,923 |
| Advair HfaFluticasone Propion/Salmeterol | 210 | $76,291 |
| Dupixent PenDupilumab | 17 | $75,048 |
| NucalaMepolizumab | 16 | $68,538 |
| Breo ElliptaFluticasone/Vilanterol | 128 | $56,920 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 105 | $53,116 |
| SymbicortBudesonide/Formoterol Fumarate | 140 | $36,680 |
| Incruse ElliptaUmeclidinium Bromide | 91 | $32,720 |
| EliquisApixaban | 38 | $26,931 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 46 | $25,038 |
| Spiriva HandihalerTiotropium Bromide | 33 | $21,937 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 90 | $19,941 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 115 | $17,780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $34 | $531,587769 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $67 | $489,672296 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $135 | $49,749161 claims |
| PfizerEliquis | $78 | $26,93138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 33 critical care medicine providers in Iowa.
Other critical care medicine in Davenport
- Humphrey WongDavenport$31K
- Andrea OdvarkoDavenport$154
- Amal El-BakushCedar Rapids$19K
- Lovkesh AroraIowa City$5K
- Charles RappaportIowa City$4K
- David KaczkaIowa City$4K
- Amith George JacobIowa City$3K
- Katherine KavanaughCedar Rapids$2K
- Gregory SchmidtIowa City$2K
- Swaroopa Rani NalamalapuWaterloo$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.